Long‑Term Lecanemab Shows 5‑Year Benefit in Early Alzheimer’s: Clarity AD Results
Long‑term lecanemab (LEQEMBI®) study shows sustained cognitive & functional gains in early Alzheimer’s, proving safety, reducing decline, and supporting early, continuous treatment.
3 minutes to read









